Bogas Gador, Mayorga Cristobalina, Martín-Serrano Ángela, Fernández-Santamaría Rubén, Jiménez-Sánchez Isabel M, Ariza Adriana, Barrionuevo Esther, Posadas Teresa, Salas María, Fernández Tahía Diana, Torres María José, Montañez María Isabel
Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil, 29009, Málaga, Spain.
Allergy Unit, Hospital Regional Universitario de Málaga, Hospital Civil, 29009, Málaga, Spain.
Clin Transl Allergy. 2020 Dec 4;10(1):57. doi: 10.1186/s13601-020-00368-1.
Analysis of cross-reactivity is necessary for prescribing safe cephalosporins for penicillin allergic patients. Amoxicillin (AX) is the betalactam most often involved in immediate hypersensitivity reactions (IHRs), and cefadroxil (CX) the most likely cephalosporin to cross-react with AX, since they share the same R1 side chain, unlike cefuroxime (CO), with a structurally different R1. We aimed to analyse cross-reactivity with CX and CO in patients with confirmed IHRs to AX, including sIgE recognition to AX, CX, CO, and novel synthetic determinants of CX.
Fifty-four patients with confirmed IHRs to AX based on skin test (ST) and/or drug provocation test (DPT) were included. Serum sIgE to AX and benzylpenicillin was determined by Radioallergosorbent test (RAST). Two potential determinants of CX, involving intact or modified R1 structure, with open betalactam ring, were synthesised and sIgE evaluated by RAST inhibition assay.
Tolerance to CX (Group A) was observed in 64.8% cases and cross-reactivity in 35.2% cases (Group B). Cross-reactivity with CO was only found in 1.8% cases from Group B. ST to CX showed a negative predictive value of 94.6%. RAST inhibition assays showed higher recognition to CX as well as to both synthetic determinants (66% of positive cases) in Group B.
Cross-reactivity with CX in AX allergic patients is 35%, being ST not enough for prediction. R1, although critical for recognition, is not the unique factor. The synthetic determinants of CX, 1-(HOPhG-Ser-Bu) and 2-(pyrazinone) are promising tools for determining in vitro cross-reactivity to CX in AX allergic patients.
对于青霉素过敏患者,开具安全的头孢菌素时,交叉反应性分析是必要的。阿莫西林(AX)是最常引发速发型过敏反应(IHRs)的β-内酰胺类药物,而头孢羟氨苄(CX)是最有可能与AX发生交叉反应的头孢菌素,因为它们具有相同的R1侧链,不像头孢呋辛(CO),其R1结构不同。我们旨在分析对AX有确诊IHRs的患者中与CX和CO的交叉反应性,包括对AX、CX、CO的特异性IgE(sIgE)识别以及CX的新型合成决定簇。
纳入54例基于皮肤试验(ST)和/或药物激发试验(DPT)确诊对AX有IHRs的患者。通过放射变应原吸附试验(RAST)测定血清中对AX和苄青霉素的sIgE。合成了两个涉及完整或修饰R1结构且β-内酰胺环开放的CX潜在决定簇,并通过RAST抑制试验评估sIgE。
64.8%的病例对CX耐受(A组),35.2%的病例有交叉反应(B组)。仅在B组的1.8%病例中发现与CO有交叉反应。对CX的ST显示阴性预测值为94.6%。RAST抑制试验显示B组中对CX以及两种合成决定簇的识别率更高(66%的阳性病例)。
AX过敏患者中与CX的交叉反应性为35%,仅靠ST不足以进行预测。R1虽然对识别至关重要,但不是唯一因素。CX的合成决定簇1-(HOPhG-Ser-Bu)和2-(吡嗪酮)是用于体外测定AX过敏患者中与CX交叉反应性的有前景的工具。